Neutrophil Extracellular Traps Sit at the Center of Necrotizing Enterocolitis Biology
Neonatal necrotizing enterocolitis is no longer easy to frame as a single inflammatory disorder. In the review, NEC is presented as a syndrome of intestinal necrosis that emerges in a developmentally vulnerable host, with overlapping inflammatory, ischemic, infectious, cardiac-related, and transfusion-associated triggers. The gut injury pattern is familiar at the bedside: feeding intolerance, abdominal distension, gastric retention, bloody stools, ileus, and systemic instability often precede more specific radiographic signs such as pneumatosis intestinalis, portal venous gas, fixed loops, and free air. The clinical challenge is not simply recognizing enteritis. It is identifying the infant who will cross into irreversible necrosis.
Within that framework, neutrophil extracellular traps emerge as more than a laboratory curiosity. NETs are extracellular DNA structures decorated with histones, myeloperoxidase, neutrophil elastase, and other granule proteins. Their core function is antimicrobial containment, but the same scaffold can injure epithelium, activate endothelium, support platelet adhesion, and promote coagulation. In NEC, those effects converge into immunothrombotic injury, where microbial defense and tissue destruction become difficult to separate.
A central strength of the review is its insistence on developmental context. Neonatal neutrophils are not miniature adult neutrophils. Term and preterm cells generally show lower stimulus-induced NET formation than adult neutrophils, and preterm cells are often even less responsive. Umbilical cord blood contains neonatal NET-inhibitory factor, or nNIF, derived from the carboxyl terminus of alpha-1 antitrypsin, and placenta-derived HTRA1 can generate NET-inhibitory peptides by cleaving alpha-1 antitrypsin. In longitudinal observations of premature infants, stimulus-induced NET formation became detectable around postnatal day 3 and appeared relatively prominent between days 3 and 14. In practical terms, that interval aligns with feeding advancement and microbial succession, the same period when NEC most often appears.
Why Developmental NET Maturation May Matter More Than a Single Marker
The review rejects the idea that one NET marker can define the biology of NEC. Extracellular DNA alone is nonspecific. Myeloperoxidase positivity alone is not enough. Citrullinated histone H3 is useful, but it does not capture every path to trap formation. NET biology depends on the stimulus, the route of formation, and the local tissue environment. Suicidal NET formation often involves reactive oxygen species, neutrophil elastase, myeloperoxidase translocation, chromatin decondensation, nuclear membrane rupture, and cell lysis. PAD4-mediated histone citrullination can promote this process, but PAD4-independent NET formation also exists. Mitochondrial DNA-containing traps have been described as well.
Clearance matters just as much as formation. DNase activity, macrophage phagocytosis, local proteolysis, complement regulators, and endothelial surfaces all influence how long NETs persist in tissue. When clearance fails, NETs become biologically expensive structures: DNA scaffolds encourage platelet adhesion and thrombin generation, activated platelets and thrombin further stimulate neutrophils, and complement amplifies recruitment and permeability. In the bowel, that loop can intensify epithelial damage, endothelial activation, microthrombosis, and systemic inflammation.
One sentence captures the bedside consequence: persistent NETs can convert a localized mucosal insult into a vascular and thrombotic injury pattern.
This is why the review emphasizes timing. Interventions that prevent NET execution are not the same as interventions that clear deposited NETs, and preventive blockade is not equivalent to treatment after injury is established. The proposed postnatal day 3–14 window is presented as a developmentally grounded hypothesis, not a validated quantitative rule. It explains why NEC is uncommon at birth but clusters later, and it also explains why broad neonatal grouping can blur disease biology. Gestational age, postnatal age, birth weight, delivery mode, chorioamnionitis, perinatal infection, antibiotics, nutrition, transfusion, and platelet-neutrophil interactions all function as biologically meaningful covariates.
Human, Animal, and Mechanistic Data Point in Different Directions for a Reason
The evidence base is convergent, but not uniform. Human surgical tissues from NEC show neutrophil infiltration with extracellular DNA, myeloperoxidase or neutrophil elastase co-localization, and citrullinated histone H3 in injured mucosa. Fecal calprotectin rises around clinical onset and has been localized to NET-like structures, suggesting that it reflects both neutrophil influx and NET release. Circulating markers such as cell-free DNA, nucleosomes, MPO-DNA complexes, NE-DNA complexes, and H3cit have also been reported in NEC, with severity correlations in some cohorts. Still, these markers are imperfect. Surgical samples often represent late disease, and circulating DNA can reflect hemolysis, necrosis, degranulation, and other non-NET sources.
Animal studies are even more instructive because they separate disease contexts. In LPS/formula/hypoxia mouse models, PAD inhibition reduced mortality and tissue injury, while systemic DNase1 reduced extracellular DNA, inflammation, oxidative stress, epithelial injury, and mortality. In contrast, a dithizone/Klebsiella model with marked bacterial translocation showed the opposite pattern: NET inhibition increased bacteremia, systemic inflammation, organ injury, and mortality. In Citrobacter rodentium infection, PAD4-dependent NETs were required for mucosal clearance. Those findings are not contradictory. They reflect differences in pathogen burden, barrier integrity, and intervention timing.
The translational message is direct. NETs may be injurious when inflammation and microvascular compromise dominate, but protective when bacterial containment is the overriding need. A blanket strategy to suppress NETs in every infant with NEC biology would ignore that distinction.
Recent mechanistic work places NETs inside a wider immunothrombotic circuit. CD177-positive neutrophil-platelet aggregates contribute to thromboinflammation through NETs in NEC. Platelet-derived exosomes can induce NET formation through a pathway attenuated by gasdermin D inhibition. IP6K1-dependent platelet polyphosphates regulate neutrophil-platelet aggregates. IL-40 deficiency inhibits NETosis and ameliorates experimental injury. Together with endothelial ferroptosis and chromatin-alarmin studies, these findings move NETs from biomarker status to effector status.
The review’s clinical point is restrained but consequential. Future NEC studies need to define which infants are in a state of dominant NET formation, which are failing NET clearance, and which depend on NET function for microbial control. That requires careful reporting of model system, infection burden, intervention timing, detection method, gestational and postnatal age, transfusion exposure, feeding status, and surgical timing. Without those details, biomarker studies will continue to mix distinct phenotypes under one label.
The unresolved question is not whether NETs matter in NEC. It is which developmental stage, which inflammatory state, and which pattern of formation-versus-clearance imbalance should guide inhibition, clearance, or preservation of NET function.